/EINPresswire.com/ -- CINCINNATI, OH--(Marketwired - June 13, 2016) - Medpace, a global full service Contract Research Organization (CRO) and International Health Management Associates, Inc. (IHMA), a full service central microbiology laboratory have announced a non-exclusive strategic alliance, designed to bring sponsors developing medical therapeutics in the infectious disease area services to support Phase I-IV global clinical studies.

Infectious disease studies have grown in complexity, with traditional microbiology methods increasingly supplemented with new molecular techniques, providing rapid and accurate data that facilitate improved understanding of disease mechanisms and enhance clinical outcomes. The development of successful infectious disease therapeutics also requires access to a truly global patient population, and sophisticated testing platforms backed by expert microbiologists, to deliver a consistent and quality driven solution to these complex studies. IHMA, a long standing laboratory leader and expert in supporting antimicrobial research will partner with Medpace for clinical studies requiring a microbiology laboratory component.

"Medpace has long recognized the benefits of specialized microbiology services as a key component of infectious disease clinical trials," said Dr. Brian Murphy, Senior Medical Director, Infectious Diseases at Medpace. "IHMA and Medpace are strongly committed to the improvement of bringing anti-infective treatments to patients. The natural evolution of our relationship is an indication of our shared philosophy of collaboration, responsiveness, flexibility, and scientific innovation."

"IHMA is very excited to combine our strong scientific microbiology expertise with the full suite of capabilities that Medpace has in place to ensure successful execution of clinical trials in the infectious disease arena," said Dan Sahm, Chief Scientific Officer and VP of Global Microbiology Services, IHMA, Inc.

ABOUT MEDPACE

Medpace is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace's physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, and neuroscience. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people worldwide with operations in 35 countries.

For more information, please visit www.medpace.com.

ABOUT IHMA

IHMA, founded in 1992, has laboratories in Schaumburg, Illinois, USA (IHMA, Inc.) and in Monthey, Switzerland (IHMA Europe Sàrl). Both locations provide global laboratory and consultation services that focus on antimicrobial research and support for small and large biopharmaceutical companies developing and marketing vaccines, antimicrobials and other anti-infective products. IHMA laboratories perform essentially all in vitro microbiology services required by biopharmaceutical companies for drug discovery, pre-IND studies, Phase I, II, III, and IV studies for anti-infective development, and post-marketing studies.

For more information, visit the IHMA website at: www.ihmainc.com

Contact
Mary Kuramoto
513-579-9911 x2523
m.kuramoto@medpace.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.